Sign in

SCYX on Nasdaq

SCYNEXIS INC

SCYNEXIS INC is a pharmaceutical preparations company based in Jersey City.1 Its shares trade on Nasdaq under the symbol SCYX.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with CASI Pharmaceuticals, Inc., Evofem Biosciences, Inc. or Prenetics Global Ltd, or pick any stock.

  • TickerSCYX on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersJersey City, New Jersey1
  • Business address1 Evertrust Plaza, 13Th Floor, Jersey City, Nj 07302-65482
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

SCYNEXIS, Inc. is dedicated to advancing innovative solutions for severe rare diseases, with our lead program in the treatment and prevention of difficult-to-treat and drug-resistant fungal infections. We are developing our proprietary antifungal platform “fungerps”, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a broad range of human fungal pathogens such as Candida and Aspergillus genera, including multidrug-resistant strains, as well as Pneumocystis , Coccidioides , Histoplasma and Blastomyces genera and most common mucorales species.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-78.0%Operating margin4
-41.8%Net margin4
449.9%Revenue growth, 20254
-17.4%Return on equity4

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

License and Service brought in 93% of the revenue SCYNEXIS INC broke down this way in fiscal 2025.

  1. License and Service$19.2M493%up 411% from 2024
  2. Product$1.4M47%
Products and services by year
Products and services20242025
License and Service$3.7M$19.2M
Product$0$1.4M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development61¢$22.3M
  • Selling, general and admin39¢$14.4M

Out of $20.6M in revenue.4 The company lost money this year.

Financial statements

Revenue567894$20.6M in 2025+16926% since 2019
0$50.0M$100.0M$150.0M2019: $121.0K$121.0K20192020: $0$020202021: $13.2M$13.2M20212022: $5.1M$5.1M2022−61%2023: $140.1M$140.1M2023+2653%2024: $3.7M$3.7M2024−97%2025: $20.6M$20.6M2025+450%
Operating income567894-$16.1M in 2025−67% since 2019
-$100.0M-$50.0M0$50.0M$100.0M2019: -$48.9M-$48.9M20192020: -$51.1M-$51.1M2020+5%2021: -$60.8M-$60.8M2021+19%2022: -$85.8M-$85.8M2022+41%2023: $72.7M$72.7M20232024: -$37.1M-$37.1M20242025: -$16.1M-$16.1M2025−57%
Net income567894-$8.6M in 2025−84% since 2019
-$100.0M-$50.0M0$50.0M$100.0M2019: -$53.7M-$53.7M20192020: -$55.2M-$55.2M2020+3%2021: -$32.9M-$32.9M2021−40%2022: -$62.8M-$62.8M2022+91%2023: $67.0M$67.0M20232024: -$21.3M-$21.3M20242025: -$8.6M-$8.6M2025−60%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
Total revenue$20.6M$3.7M
Research and development$22.3M$26.4M
Selling, general and administrative$14.4M$14.5M
Total operating expenses$36.7M$40.9M
Loss from operations-$16.1M-$37.1M
Amortization of debt issuance costs and discount$312.0K$1.7M
Interest income-$2.2M-$4.3M
Interest expense$173.0K$828.0K
Other income$0-$235.0K
Warrant liability fair value adjustment-$5.8M-$13.8M
Derivative liability fair value adjustment$0-$196.0K
Total other income-$7.5M-$16.0M
Loss before taxes-$8.6M-$21.1M
Income tax expense$0-$151.0K
Net loss-$8.6M-$21.3M
Net loss per share - basic-$0.17-$0.44
Net loss per share - diluted-$0.17-$0.44
Weighted average common shares outstanding - basic49.9M shares48.5M shares
Weighted average common shares outstanding - diluted49.9M shares48.5M shares

Compare SCYNEXIS INC with another company

Corporate structure

SCYNEXIS INC sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of SCYNEXIS INC

  • SCYNEXIS INC Jersey City, New Jersey

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What SCYNEXIS INC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Operating-lease assets (leased space)$1.8M4 Dec 31, 2025$2.1M4 Dec 31, 2024−15.6%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$21.3M4 Dec 31, 2025$16.1M4 Dec 31, 2024+32.4%
Marketable securities, current$18.8M4 Dec 31, 2025$43.2M4 Dec 31, 2024−56.6%

Properties, in its own words

On March 1, 2018, we entered into a long-term lease agreement for approximately 19,275 square feet of office space in Jersey City, New Jersey. The lease term is until July 2029, and we have the option to renew for two consecutive five-year periods from the end of the first term. We believe that our facilities under this lease are adequate for our purposes for the foreseeable future.

Item 2 of the 10-K filed Mar 4, 2026.3

Leadership

Who has led SCYNEXIS INC, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Yves J. Ribeill2014
  2. Marco Taglietti2015–2022
  3. Gonzalez David Angulo2023–now

President

  1. Yves J. Ribeill2014–2015

Chief financial officer

  1. Charles F. Osborne Jr.2014–2015
  2. Jonathan Sears Woodall2015
  3. Eric Francois2015–2021
  4. Lawrence R. Hoffman2021
  5. Ivor Macleod2022–2026
  6. Sanjay Subramanian2026–now
201520202025
Board members and other officers (23)

Timeline

  1. Sep 28, 20268-K Entered a material agreement; Regulation FD disclosure44
  2. Sep 22, 20268-K Executive or director change; Regulation FD disclosure45
  3. Sep 10, 20268-K Executive or director change; Other events46
  4. Jun 26, 20268-K Bylaws or fiscal year changed; Shareholder vote; Other events47
  5. May 29, 20268-K Bylaws or fiscal year changed48
  6. May 22, 20268-K Shareholder vote; Other events49
  7. Apr 20, 20268-K Executive or director change50
  8. Mar 31, 20268-K Entered a material agreement; Completed an acquisition or sale; Regulation FD disclosure51
  9. Mar 31, 20268-K Entered a material agreement; Unregistered sale of shares; Regulation FD disclosure52
  10. Mar 31, 20268-K Regulation FD disclosure53
  11. Oct 15, 20258-K Entered a material agreement54
  12. Jul 1, 20258-K Shareholder vote55
  13. Jan 3, 2023New chief executive Gonzalez David Angulo becomes CEO13
  14. Apr 3, 2015New chief executive Marco Taglietti becomes CEO14
  15. May 2, 2014New chief executive Yves J. Ribeill becomes CEO15

Calendar

Coming up

  1. Nov 4, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($1.36) a share, on Nov 5, 2025.56

When it reported results

  1. Mar 28, 2024Reported quarterly or annual results57
  2. Nov 9, 2022Reported quarterly or annual results58
  3. Aug 15, 2022Reported quarterly or annual results59
  4. May 12, 2022Reported quarterly or annual results60
  5. Mar 29, 2022Reported quarterly or annual results61
  6. Nov 10, 2021Reported quarterly or annual results62

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

226 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 37 major events, 66 insider forms, 40 large holders, 62 other. The latest 20:

  1. Sep 28, 20268-K EDGAR
  2. Sep 22, 20264 EDGAR
  3. Sep 22, 20263 EDGAR
  4. Sep 22, 20268-K EDGAR
  5. Sep 11, 20264 EDGAR
  6. Sep 11, 20263 EDGAR
  7. Sep 10, 20268-K EDGAR
  8. Aug 14, 2026SCHEDULE 13G/A EDGAR
  9. Aug 14, 2026SCHEDULE 13G/A EDGAR
  10. Aug 12, 2026SCHEDULE 13G EDGAR
  11. Aug 10, 2026S-8 EDGAR
  12. Aug 10, 202610-Q EDGAR
  13. Jul 20, 2026SCHEDULE 13G/A EDGAR
  14. Jul 8, 2026SCHEDULE 13G/A EDGAR
  15. Jun 30, 20264 EDGAR
  16. Jun 30, 20264 EDGAR
  17. Jun 30, 20264 EDGAR
  18. Jun 30, 20264 EDGAR
  19. Jun 30, 20264 EDGAR
  20. Jun 26, 20268-K EDGAR

The 226 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

4 open-market trades by officers, directors and large owners since October 2021: 4 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Apr 1, 2026Angulo Gonzalez DavidChief Executive OfficerBuy108,695Form 4
Sep 12, 2024Angulo Gonzalez DavidChief Executive OfficerBuy20,000$1.37$27.4KForm 4
Apr 26, 2022Taglietti MarcoChief Executive OfficerBuy75,000$3.00$225.0KForm 4
Apr 26, 2022Sukenick ScottChief Legal OfficerBuy3,500$3.00$10.5KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025David Angulo, M.D.President and Chief Executive Officer61$626.0K$1.5M75
2025Ivor MacleodChief Financial Officer$467.5K$859.2K75
2025Scott SukenickChief Legal Officer48$460.0K$833.0K75
2024David Angulo, M.D.President and Chief Executive Officer61$595.3K$2.0M75
2024Ivor MacleodChief Financial Officer$449.5K$1.2M75
2024Scott SukenickChief Legal Officer48$442.3K$1.2M75

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 39. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Great Point Partners LLC944,292$3.8M0.9%New
Squadron Capital Management LLC756,884$3.1M1.1%New
Adage Capital Partners Gp, L.l.c.543,478$2.2M0.0%New
Propel Bio Management, LLC543,478$2.2M1.2%New
Woodline Partners LP387,520$1.6M0.0%New
Vanguard Capital Management LLC296,747$1.2M0.0%New
Avidity Partners Management LP260,206$1.1M0.2%New
Kingdon Capital Management, L.l.c.247,811$1.0M0.1%New
Millennium Management LLC180,788$735.8K0.0%New
Heights Capital Management, Inc150,551$612.7K0.1%New
DAFNA Capital Management LLC135,868$553.0K0.1%New
Empery Asset Management, LP126,451$514.7K0.6%New
Geode Capital Management, LLC82,093$334.2K0.0%New
Renaissance Technologies LLC76,525$311.5K0.0%New
Vanguard Fiduciary Trust Co57,970$235.9K0.0%New
ADAR1 Capital Management, LLC49,387$201.0K0.0%New
BlackRock, Inc.41,522$169.0K0.0%New
Velan Capital Investment Management LP40,000$162.8K0.1%New
Northern Trust Corp22,385$91.1K0.0%New
Bridgeway Capital Management, LLC15,554$63.3K0.0%New
Empowered Funds, LLC15,462$62.9K0.0%New
Wealth Effects LLC13,874$56.5K0.0%New
XTX Topco Ltd12,959$52.7K0.0%New
UBS Group AG11,223$45.7K0.0%New
Dimensional Fund Advisors LP10,020$40.8K0.0%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How SCYNEXIS INC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARSCYNEXIS INC1
  • CIK0001178253
  • Employer ID (EIN)56-21816483
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company3
  • Incorporated inDelaware3
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address1 Evertrust Plaza, 13Th Floor, Jersey City, NJ 07302-65481
  • Phone201-884-54851
  • Shares outstanding9,949,609 as of Aug 1, 202611
  • Public float$25.7M as of Jun 30, 20253
  • AuditorDeloitte & Touche LLP, Morristown, New Jersey PCAOB ID 34; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceJul 10, 20021
  • Filings742 in all: 4 (270), 8-K (100), SC 13G/A (52), 10-Q (38), 3 (36), S-8 (20), SC 13G (20), 424B5 (19)1
    All 40 form types

    CORRESP (17), 144 (16), DEF 14A (15), UPLOAD (14), SCHEDULE 13G/A (13), 10-K (12), EFFECT (12), DEFA14A (11), CT ORDER (10), S-3 (10), 424B3 (8), PRE 14A (7), 4/A (6), ARS (4), S-1/A (4), SCHEDULE 13G (4), REGDEX (3), 10-K/A (2), 3/A (2), 424B4 (2), D/A (2), FWP (2), S-1 (2), 10-Q/A (1), 8-A12B (1), CERTNAS (1), D (1), DRS (1), DRS/A (1), NT 10-Q (1), S-1MEF (1), S-3/A (1)

  • Latest filingsAnnual report (10-K) Mar 4, 2026
    Quarterly report (10-Q) Aug 10, 2026
    Proxy statement (DEF 14A) Apr 30, 2026
    Latest 8-K (8-K) Sep 28, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.001 per shareSCYXNasdaq

From the cover page of the 10-K filed Mar 4, 2026 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks SCYNEXIS INC names in Item 1A of its 10-K filed Mar 4, 2026: 45 risks under these headings, as written.3

  • Risks Relating to Our Financial Condition and Need for Additional Capital
  • We have a limited history of profitability, we have only one product approved for commercial sale that is licensed to GSK, and to date we have generated limited revenue from product sales. As a result, our ability to curtail our losses and sustain profitability is unproven.
  • We expect a number of factors to cause our operating results to fluctuate on a quarterly and annual basis, which may make it difficult to predict our future performance.
  • We will continue to require substantial additional capital, and if we are unable to raise capital when needed we would be forced to delay, reduce or eliminate our development program for SCY-247 or any other product candidates we may prioritize.
  • Unfavorable U.S. and global economic conditions could adversely affect our ability to access capital.
  • Risks Relating to the Development, Regulatory Approval and Commercialization of Our Product Candidates For Human Use
  • We cannot be certain that SCY-247 will receive regulatory approval in the additional indications we are pursuing, and without regulatory approval it will not be possible to market SCY-247 for these indications. Regulatory approval is a lengthy, expensive and uncertain process and there is no guarantee that SCY-247 will be approved by the FDA for the additional indications we are pursuing.
  • Although the oral formulation of SCY-247 has been granted QIDP status and Fast Track designation, this does not guarantee that the length of the FDA review process will be significantly shorter than otherwise, or that SCY-247 will ultimately be approved by the FDA.
  • Delays in the commencement, enrollment and completion of clinical trials could result in increased costs to us and delay or limit our ability to obtain regulatory approval for SCY-247 or any future product candidates.
  • Clinical failure can occur at any stage of clinical development. Because the results of earlier clinical trials are not necessarily predictive of future results, any product candidate we or our current or potential future partners advance through clinical trials may not have favorable results in later clinical trials or receive regulatory approval.
  • We have only submitted one NDA and one efficacy supplemental NDA before, and we may be unable to do so for SCY-247 in additional indications or any future product candidate we may seek to develop.
  • The environment in which our regulatory submissions may be reviewed changes over time, which may make it more difficult to obtain regulatory approval of any of our product candidates we may seek to develop or commercialize.
The other 34 risks
  • If SCY-247 or any other future product candidates for which we receive regulatory approval do not achieve broad market acceptance, the revenue that is generated from their sales will be limited.
  • A significant use of antifungal drugs consists of treatment due to the presence of symptoms before diagnosis of the invasive fungal infections, and if recently approved diagnostic tools, or additional tools currently under development, for the quick diagnosis of invasive fungal infections are broadly used in the marketplace, the number of treatments using antifungal drugs may decrease significantly, decreasing the potential market for SCY-247.
  • If resistance to SCY-247 develops quickly or cross-resistance with echinocandins becomes more common, our business will be harmed.
  • SCY-247 and product candidates may have undesirable side effects that may delay or prevent marketing approval, or, if approval is received, require them to be taken off the market or otherwise limit their sales.
  • We expect that SCY-247 and any future product candidates we may seek to develop will face competition, and most of our competitors have significantly greater resources than we do.
  • Reimbursement decisions by third-party payors may have an adverse effect on pricing and market acceptance in the United States for SCY-247 and any future product candidates we may seek to develop. If there is not sufficient reimbursement for our products, it is less likely that our products will be purchased by patients and/or providers.
  • Healthcare policy changes may have a material adverse effect on us.
  • We expect that a portion of the market for SCY-247 and any other product candidates we may seek to develop will be outside the United States. However, our product candidates may never receive approval or be commercialized outside of the United States.
  • SCY-247 or any other future product candidates we may seek to develop, may still face future development and regulatory difficulties.
  • Pharmaceutical companies are subject to significant ongoing regulatory obligations and oversight, which may result in significant additional expense and limit our ability to commercialize our products.
  • Regulations, guidelines and recommendations published by various government agencies and organizations may affect the use of SCY-247 and any future product candidates we may seek to develop.
  • Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.
  • Uncertainties in the interpretation and application of existing, new and proposed tax laws and regulations could materially affect our tax obligations and effective tax rate.
  • Risks Related to Our Dependence on Third Parties
  • We are dependent on our license agreement with GSK to commercialize ibrexafungerp other than in the Greater China region and in the Russian Federation and certain other countries, and if GSK is not successful in commercializing ibrexafungerp in these areas, we will lose a significant source of potential revenue.
  • We are dependent on our existing third-party collaboration with Hansoh to commercialize ibrexafungerp in the Greater China region, and if Hansoh is not successful in commercializing ibrexafungerp in these areas, we will lose a significant source of potential revenue.
  • We are dependent on our existing third-party collaboration with R-Pharm to commercialize ibrexafungerp in the Russian Federation and certain other countries, and if R-Pharm is not successful in commercializing ibrexafungerp in those countries, we will lose a significant source of potential revenue.
  • We may not be successful in establishing and maintaining development and commercialization collaborations, which could adversely affect our ability to develop and commercialize product candidates.
  • We depend on third-party contractors for a substantial portion of our drug development activities and may not be able to control their work as effectively as if we performed these functions ourselves.
  • As we do not intend to own or operate facilities for manufacturing, storage and distribution of drug substance or drug product we are and will be dependent on third parties for the manufacture of SCY-247. If we experience problems with any of these third parties, the manufacturing of SCY-247 could be delayed.
  • If we fail to establish or lose our relationships with CROs, our drug development efforts could be delayed.
  • Risks Relating to Our Intellectual Property
  • It is difficult and costly to protect our proprietary rights, and we may not be able to ensure their protection.
  • We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights and we may be unable to enforce or protect our rights to, or use, our technology.
  • Risks Related to Employee Matters and Managing Growth
  • We may not be able to manage our business effectively if we are unable to attract and retain key personnel.
  • We may need to expand our operations and increase the size of our company, and we may experience difficulties in managing growth.
  • Other Risks Relating to Our Business
  • We may face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability for a product candidate and may have to limit its commercialization.
  • Our internal computer systems, or those used by our contract research organizations or other contractors or consultants, may fail or suffer security breaches.
  • Our insurance policies are expensive and protect us only from some business risks, which will leave us exposed to significant uninsured liabilities.
  • Our research and development activities could be affected or delayed as a result of possible restrictions on animal testing.
  • We are subject to stringent and evolving U.S. and foreign laws, regulations, rules, contractual obligations, policies and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences.
  • If our information technology systems or data, or those of third parties upon which we rely, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse consequences.
  • Risks Relating to Owning Our Common Stock
  • The market price of our common stock may be highly volatile.
  • Future sales and issuances of our common stock or rights to purchase common stock could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.
  • Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.
  • If we fail to comply with the continued minimum closing bid requirements of the Nasdaq Capital Market or other requirements for continued listing, our common stock may be delisted and the price of our common stock and our ability to access the capital markets could be negatively impacted.

Legal proceedings

The information called for by this Item is incorporated herein by reference to Note 6 included in Part 2, Item 8, Consolidated Financial Statements and Supplementary Data — Notes to the Consolidated Financial Statements.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75